Wright Medical Group NV (NASDAQ:WMGI) has received an average recommendation of “Buy” from the fourteen research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $35.45.
A number of brokerages have recently issued reports on WMGI. Needham & Company LLC reissued a “buy” rating and issued a $38.00 target price on shares of Wright Medical Group in a report on Wednesday, April 10th. Oppenheimer dropped their price target on 2U from $83.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday, May 8th. ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Finally, BidaskClub raised Zebra Technologies from a “hold” rating to a “buy” rating in a report on Saturday, July 6th.
Shares of Wright Medical Group stock traded up $0.08 during trading on Friday, hitting $26.41. The stock had a trading volume of 22,216 shares, compared to its average volume of 2,237,953. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.70 and a current ratio of 0.91. The stock has a market capitalization of $3.36 billion, a price-to-earnings ratio of 667.00, a P/E/G ratio of 8.10 and a beta of 0.73. The firm’s fifty day simple moving average is $29.59. Wright Medical Group has a fifty-two week low of $24.10 and a fifty-two week high of $32.86.
Wright Medical Group (NASDAQ:WMGI) last announced its earnings results on Tuesday, May 7th. The medical device company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.02. The company had revenue of $230.13 million for the quarter, compared to analyst estimates of $226.10 million. Wright Medical Group had a positive return on equity of 0.84% and a negative net margin of 20.81%. Wright Medical Group’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.01) earnings per share. On average, analysts predict that Wright Medical Group will post 0.22 earnings per share for the current year.
In other news, CAO Julie Andrews sold 1,447 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $30.65, for a total value of $44,350.55. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Andrew C. Morton sold 2,173 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $32.50, for a total value of $70,622.50. The disclosure for this sale can be found here. Insiders sold a total of 12,626 shares of company stock worth $389,339 over the last quarter. Corporate insiders own 3.80% of the company’s stock.
Several large investors have recently bought and sold shares of WMGI. Quadrant Capital Group LLC bought a new position in shares of Wright Medical Group in the 1st quarter worth $55,000. Exane Derivatives lifted its holdings in Wright Medical Group by 78.6% during the first quarter. Exane Derivatives now owns 2,777 shares of the medical device company’s stock worth $87,000 after acquiring an additional 1,222 shares in the last quarter. Cullen Frost Bankers Inc. bought a new position in Wright Medical Group during the first quarter worth about $94,000. Raymond James & Associates bought a new position in Wright Medical Group during the fourth quarter worth about $236,000. Finally, Prudential Financial Inc. lifted its holdings in Wright Medical Group by 7.3% during the fourth quarter. Prudential Financial Inc. now owns 9,744 shares of the medical device company’s stock worth $265,000 after acquiring an additional 666 shares in the last quarter.
About Wright Medical Group
Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells upper and lower extremities, and biologics products in the United States, Europe, the Middle East, Africa, Canada, Asia, Australia, and Latin America. The company offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth.
Recommended Story: How do CD ladders protect against rising interest rates?
Receive News & Ratings for Wright Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wright Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.